Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

Liaw, Yun Fan; Kao, Jia‐Horng; Piratvisuth, Teerha; Chan, Henry Lik Yuen; Chien, Rong Nan; Gane, Ed; Locarnini, Stephen; Lim, Seng Gee; Han, Kwang Hyub; Amarapurkar, Deepak; Cooksley, Graham; Jafri, Wasim; Mohamed, Rosmawati; Hou, Jin; Chuang, Wan‐Long; Lesmana, Laurentius M. Adrianto; Sollano, José D.; Suh, Dong Jin; Omata, Masao

doi:10.1007/s12072-012-9365-4

Cited by 908 publications

(1,053 citation statements)

References 241 publications

Supporting

Mentioning

1,013

Contrasting

Unclassified

Order By: Relevance

“…Clinical guidelines from Asia Pacific regions are similar, however evidence of virological breakthrough must be supported by two consecutive samples one month apart" [16,17].…”

Section: Virological Breakthrough Is Defined By the American Associatmentioning

confidence: 99%

Factors associated with HBV Virological Breakthrough

et al. 2017

View full text Add to dashboard Cite

BREAKTHROUGHBackground: Little is known about non-adherence to Hepatitis B virus (HBV) therapy.This study aimed to investigate the relationship between self-reported missed days of anti-viral therapy and HBV virological breakthrough and factors associated with virological breakthrough.Methods: A cross-sectional survey of 211 HBV patients receiving oral anti-viral therapies was undertaken at three tertiary hospitals in Sydney, Australia. Associations between 0 to > 6 missed days in the last 30 days and virological breakthrough (defined as > 10-fold rise in serum HBV DNA above nadir or after achieving virological response in the last 12 months) were examined. Logistic regression analyses determined the number of missed days most strongly associated with virological breakthrough and the associated factors. We report odds ratios and relative risks.Results: Of the 204, 32 participants (15.6%) had quantifiable HBV DNA levels (> 20 IU/mL); 15 (46.8%) of them experienced virological breakthrough. Participants reported never missing medication (n=130, 63.7%) or missing one day (n=23, 11.3%), >one day (n=23, 11.3%), 2-6 days (n=15, 7.3%) and >6 days (n=13, 6.4%). The most discriminating definition of non-adherence was missing > one day of medication

show abstract

“…Clinical guidelines from Asia Pacific regions are similar, however evidence of virological breakthrough must be supported by two consecutive samples one month apart" [16,17].…”

Section: Virological Breakthrough Is Defined By the American Associatmentioning

confidence: 99%

Factors associated with HBV Virological Breakthrough

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The majority of HCC cases are caused by chronic hepatitis B or hepatitis C infections (2). HCC, characterized by rapid recurrence and poor survival, remains a challenging disease to treat (3).…”

Section: Introductionmentioning

confidence: 99%

R-spondin 2 promotes proliferation and migration via the Wnt/β-catenin pathway in human hepatocellular carcinoma

Yin

Wang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Hepatocellular carcinoma (HCC) is a leading cause of malignant disease-associated mortality, particularly in China. The RSPO2 (R-spondin 2) gene is evolutionarily conserved in vertebrates and is involved in developmental and physiological processes. Importantly, RSPO2 has been reported to be associated with colon cancer and potentiate the Wnt/β-catenin signaling pathway. In the present study, enhanced expression of RSPO2 in HCC was observed using tissue microarray. Similarly, the expression level of RSPO2 was higher in HepG2, Huh7 and Hep3B cells but lower in Bel7404 and QGY7703 cells compared with human normal QSG7701 liver cells. Subsequently, gain-of-function studies indicated that RSPO2 promotes the proliferation and migration of QGY7703 cells based on lentivirus-based gene delivery. Furthermore, it was revealed that p21 and leptin, rather than vascular endothelial growth factor-A, are involved in the function of RSPO2 in QGY7703 cells. Particularly, the signal transducer and activator of transcription 3 (STAT3) and Wnt/β-catenin signaling pathways are involved in this process. Overexpression of RSPO2 resulted in the elevated expression of phosphorylated STAT3, β-catenin and c-Myc. Therefore, the present study is beneficial to the understanding of RSPO2-involved liver cancer transformation and drug discovery.

show abstract

“…Approximately 30% of the world's population has been infected with HBV and 350 million are persistent carriers. 2,3 At present, no effective therapy exists for HBV infection. Therefore, preventive vaccination continues to be the most cost-effective solution for HBV-related disease control.…”

Section: Introductionmentioning

confidence: 99%

Enteric trimethyl chitosan nanoparticles containing hepatitis B surface antigen for oral delivery

Farhadian

Dounighi

Avadi³

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Oral vaccination is the preferred route of immunization. However, the degradative condition of the gastrointestinal tract and the higher molecular size of peptides pose major challenges in developing an effective oral vaccination system. One of the most excellent methods used in the development of oral vaccine delivery system relies on the entrapment of the antigen in polymeric nanoparticles. In this work, trimethyl chitosan (TMC) nanoparticles were fabricated using ionic gelation teqnique by interaction hydroxypropyl methylcellulose phthalate (HPMCP), a pHsensitive polymer, with TMC and the utility of the particles in the oral delivery of hepatitis B surface antigen (HBsAg) was evaluated employing solutions that simulated gastric and intestinal conditions. The particle size, morphology, zeta potential, loading capacity, loading efficiency, in vitro release behavior, structure, and morphology of nanoparticles were evaluated, and the activity of the loaded antigen was assessed. Size of the optimized TMC/HPMCP nanoparticles and that of the antigen-loaded nanoparticles were 85 nm and 158 nm, respectively. Optimum loading capacity (76.75%) and loading efficiency (86.29%) were achieved at 300 mg/mL concentration of the antigen. SEM images revealed a spherical shape as well as a smooth and near-homogenous surface of nanoparticles. Results of the in vitro release studies showed that formulation with HPMCP improved the acid stability of the TMC nanoparticles as well as their capability to preserve the loaded HBsAg from gastric destruction. The antigen showed good activity both before and after loading. The results suggest that TMC/HPMCP nanoparticles could be used in the oral delivery of HBsAg vaccine.

show abstract

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

Cited by 908 publications

References 241 publications

Factors associated with HBV Virological Breakthrough

Factors associated with HBV Virological Breakthrough

R-spondin 2 promotes proliferation and migration via the Wnt/β-catenin pathway in human hepatocellular carcinoma

Enteric trimethyl chitosan nanoparticles containing hepatitis B surface antigen for oral delivery

Contact Info

Product

Resources

About